Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

Journal of Clinical Pharmacology

Volumn 42, Issue 11, 2002, Pages 1219-1227

  Belle, Donna J ^a,b   Ernest, C Steven ^a   Sauer, John Michael ^a   Smith, Brian P ^a   Thomasson, Holly R ^a   Witcher, Jennifer W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYATOMOXETINE; ATOMOXETINE; CYTOCHROME P450 2D6; DRUG METABOLITE; N NORATOMOXETINE; PAROXETINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SINGLE BLIND PROCEDURE; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAROXETINE; PHENOLS; PHENYL ETHERS; PROPYLAMINES; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD; SYMPORTERS; TIME FACTORS;

EID: 0036838952     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002762491307     Document Type: Article

References (29)

1. Gehlert DR, Gackenheimer SL, Robertson DW: Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 1993;157:203-206.
2. Wong DT, Threlkeld PG, Best KL, Bymaster FP: A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 1982;222:61-65.
3. Ring BJ, Gillespie J, Eckstein JA, Wrighton SA: Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Disp 2002;30:319-323.
4. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L: Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985;25:296-301.
5. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, et al: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75.
6. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, et al: The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-287.
7. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265.
8. Lane RM: Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11:31-61.
9. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenber D, Allison J, et al: Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-291.
10. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF: Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-355.
11. Özdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997;62:334-347.
12. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000.
14. Weiss G: Followup studies on outcome of hyperactive children. Psychopharmacol Bull 1985;21:169-177.
15. Barkley FA, Fischer M, Edelbrock CS, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990;29:546-557.
16. Munir K, Biederman J, Knee D: Psychiatric comorbidity in patients with attention deficit disorder: A controlled study. J Am Acad Child Adolesc Psychiatry 1987;26:844-848.
17. Biederman J, Newcorn J, Sprich S: Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-577.
18. Guengerich FP: Human cytochrome P450 enzymes, in: Ortiz de Montellano PR (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry. New York: Plenum, 1995;473-535.
19. Caccia S: Metabolism of the newer antidepressants: An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998;34:281-302.
20. Preskorn SH: Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(suppl.):1-21.
21. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM: Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 2000;67:283-291.
22. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, et al: Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmcology 1996;128:398-407.
23. Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, et al: Determinants of interindividual variability and extent of CYP2D6 and CYPIA2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Pyschopharmacol 1998;18:198-207.
24. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI: Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997;44:495-498.
25. Hemeryck A, De Vriendt C, Belpaire FM: Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 1999;54:947-951.
26. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y: The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995;40:481-485.
27. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-131.
28. Martin DE, Zussman BD, Everitt DE, Benincosa LJ, Etheredge RC, Jorkasky DK: Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol 1997;17:451-459.
29. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 2001;108(5) [Online]. Retrieved from http://www.pediatrics.org/cgi/content/full/108/5/e83